Terns Pharmaceuticals (TERN)
(Delayed Data from NSDQ)
$7.15 USD
-0.13 (-1.79%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $7.16 +0.01 (0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TERN 7.15 -0.13(-1.79%)
Will TERN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TERN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TERN
Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's is How to Trade
Terns Pharmaceuticals, Inc. (TERN) Is Up 15.12% in One Week: What You Should Know
TERN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Take the Zacks Approach to Beat the Market: Uber, Baidu, AssetMark in Focus
Are You Looking for a Top Momentum Pick? Why Terns Pharmaceuticals, Inc. (TERN) is a Great Choice
Zacks.com featured highlights include Terns Pharmaceuticals, AllianceBernstein Holding and ALLETE
Other News for TERN
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Ventyx Biosciences (VTYX) and Walgreens Boots Alliance (WBA)
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Buy Rating Upheld for Terns Pharmaceuticals Amid Strong Prospects for TERN-701 and Financial Stability
Tern Plc Updates Share Capital and Voting Rights
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences